SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
Discover1093.HK
HealthcareHKEXHKD

CSPC Pharmaceutical Group

HK$00123456789.0012345678900123456789+16.6%
52w low (est.) HK$6.49HK$10.15 52w high (est.)
Peers
Market data
Market cap
HK$92.50B
52-week range
HK$6.53 – HK$11.63
Beta (vs market)
0.72
Sector
Healthcare
Valuation
P/E ratio
20.8x
DCF fair value
HK$3.87
Margin of safety
-52.1%
Forward P/E
11.0x
PEG ratio
0.33
Dividend yield
3.70%
Quality & efficiency
Moat score
63/100
Return on equity
9.6%
Profit margin
12.8%
Debt / equity
0.02
Growth & analysts
Revenue growth (YoY)
-7.8%
Analyst target
HK$11.61
Target upside
+43.6%
Analysts covering
22

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Valuation

ValueGrowthProfitHealthIncome43QUALITY
Overall Rating
47
Hold
Hold
Moat Score63
DCF Intrinsic Value
HK$3.87-52.1% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
HK$92.50B
P/E Ratio
20.8
Dividend Yield
3.70%
Revenue Growth
-7.8%
Profit Margin
12.8%
ROE
9.6%
Debt / Equity
0.02
Beta
0.72
Dividend Aristocrats
vs Healthcare sector:P/E 21 vs 28 · cheaperMoat 63 vs 7Yield 3.70% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · 1093.HK